Overview: ToRCH Panel IgG
Introduction: The ToRCH Panel IgG is a diagnostic tool designed for congenital infection screening using serum samples. In India, past ToRCH exposure (Toxoplasma, Rubella, CMV, HSV IgG positivity) is common (Toxoplasma ~10-20 percent, CMV ~80-90 percent, Rubella declining), indicating immunity but requiring IgM/avidity for recent infection risk in pregnancy. High morbidity from under-testing in rural/low-SES pregnant women, limited serology labs, delayed risk stratification leading to unnecessary anxiety or missed congenital defects. Per obstetrics practices aligned with ICMR, FOGSI, and National Health Mission guidelines, the test employs immunoassay for Toxoplasma IgG, Rubella IgG, CMV IgG, and HSV IgG over 1â€"2 days with high accuracy, valuable for baseline immunity screening in early pregnancy. This diagnostic falls under infectious disease screening and targets pregnant women in first trimester or high-risk, addressing accurate detection to guide further IgM/avidity or reassurance. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early ToRCH immunity profiling and reducing congenital infection burden. Its serum-based approach ensures reliable IgG detection.
Other Names: TORCH IgG Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry/immunology/clinical pathology, compliant with 2025 standards.
Historical Milestone: ToRCH IgG screening standard in antenatal care; in India, routine in high-risk pregnancies.
Purpose: The test assesses 4 parameters including Toxoplasma IgG to guide congenital infection screening, assess past exposure/immunity, inform further testing.
Test Parameters: 1. Toxoplasma IgG, 2. Rubella IgG, 3. CMV IgG, 4. HSV IgG.
Pretest Condition: No fasting required; patients should be pregnant.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on gestational age, prior infections.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of recent infection including fetal defects, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive IgG indicates past exposure/immunity; negative flags susceptibility, necessitating specialist input.
Specialist Consultation: Obstetricians or infectious disease specialists should be consulted for management.
Additional Supporting Tests: IgM, avidity for recent infection confirmation.
Test Limitations: IgG only (no acute status); comprehensive approach required.
References: Indian Journal of Obstetrics and Gynaecology 2024, TORCH Studies India 2023.
